Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert, presented “Results of the PRIME Trial Biparametric Versus Multiparametric MRI for Prostate Cancer Detection – Impli” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 17, 2024, in San Diego, California.
>
How to cite: Kasivisvanathan, Veeru. “Results of the PRIME Trial Biparametric Versus Multiparametric MRI for Prostate Cancer Detection – Impli.” October, 2024. Accessed Feb 2025. https://grandroundsinurology.com/results-of-the-prime-trial-biparametric-versus-multiparametric-mri-for-prostate-cancer-detection-impli/
Results of the PRIME Trial Biparametric Versus Multiparametric MRI for Prostate Cancer Detection – Impli – Summary
Veeru Kasivisvanathan, MBBS, BSc, FRCS, PhD, MSc, PGCert, shares results from the PRIME study, which explores the potential of biparametric MRI (bpMRI) as a non-inferior alternative to multiparametric MRI (mpMRI) for diagnosing clinically significant prostate cancer. In this 14-minute presentation, Dr. Kasivisvanathan shares that the results demonstrate that bpMRI detects clinically significant cancers at rates comparable to mpMRI, with no significant differences in false-positive rates or biopsy recommendations. Quality control analyses confirmed that imaging quality was critical, with optimization efforts ensuring high diagnostic reliability across centers.
The study concludes that bpMRI is a viable, cost-effective alternative for primary prostate cancer diagnosis, offering broader access without compromising clinical outcomes. The adoption of bpMRI as the new standard of care has the potential to streamline diagnostics and expand access to advanced prostate imaging globally.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
